Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
Tel: 317-276-2000
Website: http://www.lilly.com/
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. We also have been committed to investing in our employees – through competitive salaries, training and development, health, and the opportunity to do good. The pharmaceutical industry is a complex, rapidly changing environment and we’re looking for people who are determined to make life better for people around the world. Visit https://careers.lilly.com for more information.
Stock Symbol: LLY
Stock Exchange: NYSE
We discover life-changing medicines. We commit to diversity and inclusion. We volunteer millions of hours. We make life better. We are Lilly.
2271 articles with Eli Lilly and Company
-
Lispro Injection is a generic of Eli Lilly's Humalog that is now available to diabetes patients at a 50% lower list price.
-
Lilly's Lower-Priced Insulin Now Available
5/22/2019
List price of Lilly's Insulin Lispro Injection 50 percent less than branded Humalog
-
Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions
5/21/2019
In an oral presentation from the Digestive Disease Week medical conference in San Diego, California today, Eli Lilly and Company (NYSE: LLY) announced new safety and efficacy data for mirikizumab in patients with moderately- to severely active Crohn's disease.
-
Lilly to Participate in UBS Global Healthcare Conference
5/16/2019
Christi Shaw, president of Lilly Bio-Medicines, will participate in a fireside chat at 9:30 a.m., Eastern Time.
-
Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2019 Annual Meeting
5/16/2019
Flatiron Health announced 16 abstracts accepted for presentation at the 2019 American Society for Clinical Oncology Annual Meeting, which will be held May 31 - June 4 in Chicago.
-
Innovent Will Provide Key Results Update of Several Clinical Studies at 2019 ASCO Annual Meeting
5/16/2019
Oral presentation on the results of sintilimab for relapsed/refractory extranodal NK/T cell lymphoma
-
Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer
5/15/2019
Eli Lilly and Company announced that data from a number of studies across the company's oncology product portfolio will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019.
-
Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma
5/13/2019
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha-fetoprotein (AFP) of ≥400 ng/mL and have been treated with sorafenib.
-
ICON Awarded Clinical Research Team of the Year and Best in Health Economics and Outcomes Research
5/13/2019
ICON Wins Multiple Awards at the 2019 Clinical and Research Excellence Awards
-
The drug was approved as a second-line treatment for HCC patients who have an alpha-fetoprotein biomarker.
-
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
-
AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience
5/8/2019
The lasmiditan Phase 3 program encompassed more than 4,000 patients and 20,000 migraine attacks
-
Elanco Appoints Art A. Garcia to Board of Directors
5/8/2019
Elanco Animal Health announced the appointment of Art A. Garcia, recently retired executive vice president and chief financial officer of Ryder System Inc., to the Board of Directors.
-
Two Clinical Studies with IBI301, a Biosimilar Candidate to Rituximab, Met Primary Endpoints
5/8/2019
Innovent Biologics, Inc. and Eli Lilly and Company jointly announced that IBI301 which is sold under the brand name MabThera/Rituxan has met pre-defined primary endpoints in two randomized clinical trials comparing IBI301 to rituximab, namely: a phase III clinical trial in patients with diffuse large B-cell lymphoma and a pharmacokinetic study in patients with CD20-positive B-cell lymphoma.
-
AAN 2019: Pooled Analyses of Two Emgality® (galcanezumab-gnlm) Phase 3 Studies Show Reduction in Monthly Migraine Headache Days in Low- and High-Frequency Episodic Migraine Subgroups
5/6/2019
Eli Lilly and Company announced the upcoming presentation of results from pooled subgroup analyses of efficacy data from the Phase 3 EVOLVE-1 and EVOLVE-2 studies.
-
Lilly Declares Second-Quarter 2019 Dividend
5/6/2019
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2019 of $0.645 per share on outstanding common stock.
-
In the study, tadalafil, the active ingredient in Cialis and Viagra, reversed the effects of heart failure, including the breathlessness associated with it.
-
Quite a few companies recently released results from late-stage clinical trials. Here’s a look at some of the top stories, from AveXis, Urovant, Lilly, and more.
-
Lilly to Present New Data at AAN 2019 on Emgality® (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders Portfolio
5/2/2019
19 abstracts to be presented, including Phase 3, eight-week data on Emgality for the preventive treatment of episodic cluster headache in adults, featured in a plenary presentation
-
For those select few who achieve the role of chief executive officer of a multi-national corporation, the compensation packages are typically quite large – especially when compared to the average salaries of company employees.